Urotronic has raised $6.1 million in an equity offering involving 21 investors, according to a document filed with the SEC this week.
The Minnesota-based company has not publicly stated how it plans to spend its newly-acquired funds. Urotronic is developing a drug-coated balloon catheter designed to treat urethral strictures in men.
Get the full story at our sister site, Drug Delivery Business News.
The post Drug-coated balloon developer Urotronic raises $6m appeared first on MassDevice.